What Avidas Pharmaceuticals does

Avidas Pharmaceuticals LLC is a privately-held specialty pharmaceutical company headquartered in Doylestown, Pennsylvania, focused on age-related disorders and diseases in dermatology, endocrinology, and women's healthcare. The company does not develop or manufacture its own molecules; rather, it identifies and acquires novel specialty therapeutics, including late-stage development drugs, through in-licensing arrangements and partnership-driven acquisitions. Founded and led by Margie Gardner, whose 25+ years of pharmaceutical experience includes senior commercial leadership roles at SmithKline, GlaxoSmithKline, Merck, and most recently as Senior Vice President at King Pharmaceuticals, the company positions its commercialization expertise as its primary value proposition to potential licensors.

Avidas generates revenue by commercializing its in-licensed product portfolio through a US-wide direct field sales force, with 25+ sales territory positions open across major metropolitan markets and regional sales leadership overseeing the Northeast and Southwest. The go-to-market motion is enterprise field sales targeting healthcare providers in its three therapeutic focus areas, with supporting activities in product expertise, medical education, and customer service. The company is not vertically integrated, has no disclosed institutional investors or funding rounds, and operates entirely on a domestic US basis with no international footprint signaled.

The business model is asset-light and partnership-dependent: Avidas's value capture is tied to its ability to source attractive in-licensing opportunities, execute US commercial launches, and grow specialty pharma sales. No specific in-licensed products are named in the available data, and no revenue, funding, or customer concentration figures are disclosed. The company's stated growth strategy is to continuously expand its in-licensed portfolio within and potentially beyond its three named therapeutic areas, leveraging its commercial infrastructure and management's track record of product launches.

Name

Avidas Pharmaceuticals

Legal name

Avidas Pharmaceuticals LLC

Website

https://avidaspharma.com

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Avidas Pharmaceuticals is a privately-held US specialty pharmaceutical company that in-licenses and commercializes novel therapeutics in dermatology, endocrinology, and women's healthcare via a nationwide direct field sales force serving healthcare providers and patients.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

Keywords

• Specialty pharmaceuticals
• Dermatology therapeutics
• Women's healthcare drugs
• Endocrinology medicines
• In-licensed pharmaceuticals

Headquarters

HQ city

Doylestown

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

1. Pharmaceutical Product Commercialization: Avidas generates revenue through commercializing specialty pharmaceutical products acquired via in-licensing arrangements and partnerships. The company identifies and acquires novel specialty therapeutics including late-stage development drugs, then grows sales through their commercial infrastructure.

Go-to-market motion1 record

Distribution channels1 record

Core offering

Avidas Pharmaceuticals identifies and acquires novel specialty therapeutics (including late-stage development drugs) in dermatology, endocrinology, and women's healthcare through in-licensing and partnerships, then commercializes these branded pharmaceutical products across the United States using a field-based direct sales force.

Product overview

Avidas Pharmaceuticals is a privately-held specialty pharmaceutical company focused on identifying, acquiring, and commercializing novel specialty therapeutics in dermatology, endocrinology, and women's healthcare. The company does not manufacture its own products but rather operates as an in-licensing and partnership-driven entity, seeking to in-license branded pharmaceutical products including late-stage development drugs. The company's business model centers on strategic partnerships and acquisitions to grow specialty medicine portfolios rather than operating a unified product platform.

Differentiator

Problem solved

Functional benefit

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Companies with Specialty Product PortfolioscoreOthersAvidas is actively seeking partnership opportunities for specialty product licenses or acquisitions in dermatology, endocrinology, and women's healthcare. The company positions itself as an outstanding partner for companies seeking to drive sales of innovative specialty products, offering commercialization expertise and a successful track record of product launches.

Recent moves4 records

Expansion highlights4 records

Direct peers

• TherapeuticsMD: Specialty pharmaceutical company focused on women's health with a commercial sales force targeting healthcare providers, directly overlapping Avidas' women's healthcare vertical and in-licensing/commercialization model.
• Merz Therapeutics: Specialty pharmaceutical company focused on dermatology and neurology with an active US commercial sales force, comparable to Avidas in scale and therapeutic category overlap, particularly in dermatology.
• Mission Pharmacal: Privately-held specialty pharmaceutical company commercializing niche therapeutics across multiple therapeutic categories with US sales coverage — closely mirrors Avidas' in-licensing/commercialization model and specialty focus.
• Noven Pharmaceuticals: Specialty pharma with historic focus on women's health and dermatology transdermal products, operating through US physician-channel sales — directly comparable therapeutic verticals and commercialization approach.

Broad incumbents

• Organon & Co. Large women's health and biosimilars specialty pharma formed from Merck's spinoff, serving OB/GYNs and endocrinologists with a broad portfolio — competes with Avidas' women's healthcare and endocrinology focus at a much larger scale.
• Galderma: Global dermatology specialty pharmaceutical leader with established US sales infrastructure, competing directly for prescribers in Avidas' dermatology vertical — though with a much broader product portfolio.
• Endo International: Specialty pharmaceutical company with established franchises in women's health, endocrinology, and dermatology — competing with Avidas across all three therapeutic areas, but at materially larger scale.
• Amneal Pharmaceuticals: Diversified specialty and generic pharmaceutical manufacturer with US commercial infrastructure, overlapping with Avidas in specialty therapeutics distribution and the same therapeutic categories.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

• Facebookfacebook.com/avidaspharma
• LinkedInlinkedin.com/company/avidas-pharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avidas Pharmaceuticals